Bridgebio
Founded 2014 Β· 7 known investors
BridgeBio is a biopharmaceutical company that develops medicines for genetic diseases and cancers driven by specific genetic mutations, with a pipeline spanning conditions such as transthyretin amyloidosis, limb-girdle muscular dystrophy, achondroplasia, and hypoparathyroidism. Its programs range from preclinical stages through to approved therapies.
Biotech
Investors Β· 7
Frequently asked questions
- What does Bridgebio do?
- BridgeBio is a biopharmaceutical company that develops medicines for genetic diseases and cancers driven by specific genetic mutations, with a pipeline spanning conditions such as transthyretin amyloidosis, limb-girdle muscular dystrophy, achondroplasia, and hypoparathyroidism. Its programs range from preclinical stages through to approved therapies.
- Who are Bridgebio's investors?
- Bridgebio's investors include Aisling Capital, Amzak Health, EcoR1 Capital, Frazier Life Sciences, HEALTHCARE ROYALTY PARTNERS, Longwood Fund, Sequoia Capital.